Compare RCKY & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKY | IFRX |
|---|---|---|
| Founded | 1932 | 2007 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 352.5M | 303.4M |
| IPO Year | 1996 | 2017 |
| Metric | RCKY | IFRX |
|---|---|---|
| Price | $46.31 | $2.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $40.00 | $6.25 |
| AVG Volume (30 Days) | 63.1K | ★ 879.9K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.71% | N/A |
| EPS Growth | ★ 94.74 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $270,408,000.00 | N/A |
| Revenue This Year | $8.12 | N/A |
| Revenue Next Year | $4.90 | N/A |
| P/E Ratio | $23.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.30 | $0.80 |
| 52 Week High | $53.01 | $2.95 |
| Indicator | RCKY | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 51.16 | 58.65 |
| Support Level | $31.90 | $0.83 |
| Resistance Level | $48.70 | $2.94 |
| Average True Range (ATR) | 1.48 | 0.12 |
| MACD | -0.51 | 0.03 |
| Stochastic Oscillator | 18.51 | 73.58 |
Rocky Brands Inc is a designer, manufacturer, and marketer of premium footwear and apparel under brands such as Muck, XTRATUF, Rocky, Durango, Georgia Boot, Lehigh, Ranger, and the licensed brand Michelin. The company operates through three segments, with the wholesale segment generating the majority of revenue through sales of footwear and accessories to sporting goods stores, outdoor specialty stores, online retailers, marine stores, independent retailers, mass merchants, retail uniform stores, and specialty safety shoe stores. The retail segment focuses on direct-to-consumer sales through e-commerce platforms and company-operated stores, while the contract manufacturing segment includes sales to the U.S. military, private label production, and sourcing arrangements for customers.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.